Form 4 Filing for Apogee Therapeutics, Inc.

Michael Henderson, the CEO and a director of Apogee Therapeutics, Inc. (APGE), reported the sale of 80,000 shares of common stock on June 22, 2026. The shares were sold under a Rule 10b5-1 trading plan adopted on August 13, 2025. The weighted average sale price was $132.54, with individual transactions ranging from $132.50 to $132.68. Following this transaction, Henderson owns 1,015,987 shares of Apogee Therapeutics stock.